Business Wire

Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
Business Wire

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
Medscape

FDA Approves Extended-Release Clonidine for Pediatric ADHD

October 7, 2010 — The US Food and Drug Administration (FDA) has approved clonidine hydrochloride, 0.1-mg and 0.2-mg, extended-release tablets (Kapvay; Shionogi Inc ...
Monthly Prescribing Reference

Onyda XR, a Nonstimulant Liquid ADHD Medication, Now Available

Credit: Tris Pharma Onyda XR is supplied as an orange-flavored oral suspension containing clonidine hydrochloride 0.1mg per mL. Onyda XR is the first nonstimulant liquid ADHD medication with nighttime ...
Healthline

Onyda XR for ADHD in children

Onyda XR is an FDA-approved, orange-flavored liquid for children ages 6 years and older. It’s given at bedtime and is ideal for those who find swallowing pills difficult. Onyda XR can significantly ...